Key result
Childhood acute lymphoblastic leukemia survivors experience medical late effects from treatments like anthracyclines that increase their risk of premature death due to heart and vascular disease.
Answers are grounded in this paper and cite their sources.
Childhood ALL survivors are at increased risk for long-term cardiac and vascular disease, necessitating interventions to improve long-term outcomes.
Survival of childhood acute lymphoblastic leukemia (ALL) is one of the greatest medical success stories of the last four decades. Unfortunately, childhood ALL survivors experience medical late effects that increase their risk of morbidity and premature death, often due to heart and vascular disease. Research has helped elucidate the mechanisms and trajectory of direct damage to the heart from treatment exposure, particularly to anthracyclines, and has also contributed knowledge on the influences of related chronic conditions, such as obesity and insulin resistance on heart health in these survivors. This article summarizes the key issues associated with early morbidity and mortality from cardiac-related disease in childhood ALL survivors and suggests directions for interventions to improve long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Ness et al. (2011) conducted a review in Childhood acute lymphoblastic leukemia (ALL). Childhood ALL treatment (particularly anthracyclines) was evaluated. Childhood acute lymphoblastic leukemia survivors experience medical late effects from treatments like anthracyclines that increase their risk of premature death due to heart and vascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: